

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

FIRST IMPLANTATION IN THE FIM CLINICAL TRIAL OF Sutra Hemi-valve TRANSCATHETER MITRAL VALVE REPAIR SYSTEM

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that recently, Sutra Medical, Inc. (“**Sutra**”), a company in which the Group holds a strategic investment, successfully completed the first implantation in the first-in-man (“**FIM**”) clinical trial of its Sutra Hemi-valve Transcatheter Mitral Valve Repair System. The procedure was performed at Waikato Hospital in New Zealand on an 83-year-old high-risk patient with severe functional mitral regurgitation (“**MR**”), a condition for which conventional treatment options were unsuitable. The patient recovered well and was discharged from the hospital on the third day.

Reference is made to the Company’s announcement dated August 27, 2021, the Company entered into a stock purchase agreement with Sutra, a U.S.-based medical device company that designs and develops transcatheter solutions to treat valvular heart diseases. As of the date of this announcement, the Company is the second largest shareholder of Sutra, after the founding team of Sutra. Sutra’s key product candidate, Sutra Hemi-valve, is a novel posterior leaflet replacement that restores mitral valve function by coapting seamlessly with the native anterior leaflet, eliminating MR without obstructing left ventricular outflow tract.

THE COMPANY CANNOT GUARANTEE THAT Sutra Hemi-valve WILL BE DEVELOPED OR ULTIMATELY MARKETING SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, September 11, 2025

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP, Mr. Huacheng WEI as independent non-executive Directors.